Preparation and Evaluation of Ocuserts for Increasing the Bioavailability of an Antifungal Drugs
Kaushal Kumar1*, Mohd Faeek2and Nida Parveen3
1Assistant Professor MJP Rohilkhand University, Bareilly, UP, India
2Department of Pharmacy, MJP Rohilkhand University, Bareilly, UP, India
3Department of Pharmacy, Shri Ram Murti Smarak College of Engineering and Technology, Bareilly, UP, India
*Corresponding Author: Kaushal Kumar, Assistant Professor MJP Rohilkhand University, Bareilly, UP, India.
September 02, 2020; Published: September 28, 2020
The main aim of the present study is to formulate an effective ocular insert of Clotrimazole (an antifungal drug), which can produce a better ocular therapy against ocular fungal infections by increased bioavailability through increased drug-eye contact time and controlling the trans-corneal permeation of drug. We intend to optimize the formulation to show constant release of drug for maintenance of dose over a prolonged period of time. For the purpose we prepared ocular insert formulations of Clotrimazole. Various formulations were prepared by use of different polymers, HPMC, EC and combination of both in different proportions 2%, 3% and 4%. The prepared formulations were evaluated for various physical and analytical parameter related to appearance, durability, uniformity of drug contents, in-vitro and in-vivo release of drug and for stability. Ocuserts of Clotrimazole were prepared by solvent casting method followed by preparing the drug reservoir film and rate controlling membrane separately. Evaluation of ocular inserts for weight and thickness variation were carried out and analyzed by ANOVA. The % drug release from the selected formulation containing HPMC, were found to be 91.78 ± 2.436 at the end of 360 minutes. From current study we can conclude that by using different polymer in rate controlling membrane of an ocusert, release rate of drug from ocusert can be controlled or altered.
Keywords: Ocusert; Clotrimazole; HPMC; EC; ANOVA
- Jain N.K. “Controlled and novel drug delivery”. First Edition 1997, Reprint 2009, CBS publishers and distributors, 11 Darya Ganj, New Delhi-110002 (India) (1997): 82-89.
- Beringer Paul., et al. “Remington the science and practice of pharmacy”. 21st edition 2005, third Indian reprint 2009, Wolter kulwer publication (India) Pvt. Ltd., New Delhi (2005): 850-862.
- Thamizhvanan K., et al. “Current status and advanced approaches in ocular drug delivery system”. IJCP and CR2 (2012): 77-82.
- Cheien YW. “Drugs and the pharmaceutical sciences novel drug delivery systems”. Second edition, revised and expanded, volume 50, Informa health care USA inc. 52 Vanderbit avenue New York NY 10017, page no. 269-270.
- Thakur Richa and Swami Gaurav. “Promising implication of ocuserts in ocular disease”. JDDT 2 (2012): 18-19.
- Gamal El SS., et al. “Formulation and evaluation of Acyclovir ophthalmic inserts”. AJPS2 (2008): 58.
- Imam Sarim., et al. “Novel ocular dosage form in the treatment of glaucoma”. The Pharma Research 1 (2009): 76-78.
- Gevariya Hitesh B. “Formulation and evaluation of sustained release ocular drug delivery system for an anti-glaucoma drug”. Saurashtra University (2013): 1-21.
- Bankar GS and Rhodes CT. “Drug and the pharmaceutical sciences modern pharmaceutics”. Second edition, revised and expanded, Volume 40, Marcel Daker, inc., 270 Madison Avenue, New York, New York 10016, page no. 573-574.
- Brahmankar DM and Jaiswal S.B. “Biopharmaceutics and pharmacokinetics a treatise, second edition, reprint 2010, Vallabh prakashan New Delhi-110088. 473.
- Kumar KP Sampath., et al. “Ocular inserts novel controlled drug delivery system”. TPIJ12 (2013): 1-14.
- Karthikeyam D. “The concept of ocular inserts as drug delivery systems: An overview”. AJP (2008): 194-196.
- Dabhi V., et al. “Ocular inserts as controlled drug delivery systems”. IJPRBS5 (2014): 468-480.
- Asija Rajesh., et al. “Ocular drug delivery system ocular insert”. IJUP&BS2 (2012): 30-38.
- Rasool Abdul KB and Hiba MS. “Development and clinical evaluation of Clotrimazole –β- cyclodextrin eye drops for the treatment of fungal keratitis”. AAPS PharmSciTech 3 (2012): 883-889.
- Hashem M F., et al. “Formulation, characterization and clinical evaluation of micro-emulsion containing Clotrimazole for topical delivery”. AAPS PharmSciTech3 (2011): 879.
- Bansal S., et al. “Nanaocrystals: current strategies and trends technology”. 4 (2012): 6.
- Jain NK. “Introduction to novel drug delivery system”. first edition-2010, Vallabh prakashan, C-5, SMA coop. industerial estate, GT karnal road, Delhi-110033, page no. 115.
- Dinda S.C. “Advances in pharmaceutical technology”. Pharmamed press 4-4-316, Giriraj Lane Sultan Bazar, Hyderabad -500095. (2011): 398-401.
- Shankar V., et al. “A text book of novel drug delivery system”. 2012, Pharmamed press 4-4-316, Giriraj Lane Sultan Bazar, Hyderabad -500095. Page no. 398-401.
- Parmar B Ramesh and Dr HM Tank. “Design, formulation and evaluation of reservoir type controlled released Moxifloxacin hydrochloride ocular inserts”. AJRPS1 (2013): 19-24.
- Potu Rao Appa and Veera Reddy PR. “Design and evaluation of ocular inserts for controlled drug delivery of Ketorolac tromethemine”. World Journal of Pharmaceutical Research4 (2014): 722-734.
- Singh RK and Khatri OP. “A scanning electron microscope based new method for determining degree of substitution of sodium carboxy methyl cellulose”. Journal of Microscopy 246 (2012): 43-52.
- Product monograph. “Canesten 1% topical cream Clotrimazole”. Bayer Inc. 77 BelfieldToronto, Ontario, (2011) 2-19.